Microbial preparation for regulating oral flora and application thereof

Abstract

The invention relates to a microbial preparation for regulating oral flora and application of the microbial preparation. A bacterial strain in the microbial preparation for regulating the oral flora consists of a lactobacillus reuteri LR108 bacterial strain and a lactobacillus plantarum LP194 bacterial strain, and the bacterial strain in the microbial preparation for regulating the oral flora consists of a lactobacillus reuteri LR108 bacterial strain and a lactobacillus plantarum LP194 bacterial strain. The microbial preparation can regulate oral flora, has good copolymerization ability and inhibition effect on porphyromonas gingivalis bred in the oral cavity, reduces colonization of the porphyromonas gingivalis in the oral cavity, and reduces inflammatory factors, thereby promoting oral health. Wherein the LR108 strain and the LP194 strain have excellent self-agglutination and hydrophobicity, and have a positive effect on adhesion with intestinal tracts.

Description

Technical Field

[0001] The invention belongs to the technical field of probiotics and relates to a microbial preparation for regulating oral flora and an application thereof. Background Art

[0002] Chronic periodontitis (CP) is a chronic inflammation of periodontal tissue caused by multiple factors. In healthy animals, the periodontal pathogens maintain a balance with the body's immune response, maintaining the homeostasis of oral flora and the health of periodontal tissue. When the balance between subgingival plaque and the host is broken due to certain factors, the oral microecology is out of balance, leading to the occurrence of periodontitis. Porphyromonas gingivalis is a major pathogen that causes periodontal disease. A large number of studies have shown that periodontitis can cause chewing dysfunction, poor nutrient absorption, bad breath, gingival bleeding and other symptoms. In addition, periodontitis is closely related to other systemic diseases, including oral cancer, respiratory tract infection, coronary heart disease, digestive tract disease, cardiovascular disease, diabetes, etc. At present, the main clinical treatment is mechanical removal (scaling, root planing), antibiotic-assisted treatment and surgical intervention when necessary. However, there are problems such as the treatment effect is limited by individual oral hygiene habits, high costs and postoperative discomfort.

[0003] The oral cavity is one of the environments with the highest concentration of microorganisms in the human body. These microorganisms coexist harmoniously and maintain a steady state related to oral health. Some local factors may cause the microbiome to shift to a pathogenic state of dysbiosis. Oral microecological regulation technology can achieve the purpose of preventing and treating periodontitis by improving the oral microecological environment and reducing the growth of harmful bacteria.

[0004] Probiotics are active microorganisms, and proper intake is beneficial to the health of the host. Probiotics mainly work by inhibiting pathogens. They can produce bactericidal bioactive peptides such as lactobacilli, lactic acid, hydrogen peroxide, and similar inhibitory substances, or compete with pathogens for nutrients and binding sites, or directly kill pathogens. In addition, probiotics also improve barrier function by regulating signaling pathways and local and systemic host immune inflammatory responses. Therefore, the development of probiotic preparations that regulate oral flora and improve oral diseases is meaningful for promoting oral health. Summary of the invention

[0005] In view of the deficiencies of the prior art, the object of the present invention is to provide a microbial preparation for regulating oral flora and its application.

[0006] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0007] In a first aspect, the present invention provides a microbial preparation for regulating oral flora, wherein the strains in the microbial preparation for regulating oral flora are composed of Lactobacillus reuteri LR108 strain with a preservation number of CDMCC No: 63095 and Lactobacillus plantarum LP194 strain with a preservation number of CGMCC 21766.

[0008] The present invention develops a new probiotic intervention strategy for regulating oral flora, that is, Lactobacillus reuteri LR108 strain and Lactobacillus plantarum LP194 strain are compounded to form a new microbial preparation, which can regulate oral flora, has good copolymerization ability and inhibitory effect on Porphyromonas gingivalis growing in the oral cavity, reduces the colonization of Porphyromonas gingivalis in the oral cavity, reduces inflammatory factors, and thus promotes oral health. Among them, LR108 strain and LP194 strain have excellent self-aggregation and hydrophobicity, and have a positive effect on adhesion to the intestine.

[0009] Moreover, when the amount of bacteria used is the same, the combination of the two strains significantly improves the above-mentioned effects compared with a single LR108 strain or a single LP194 strain. That is, there is a potential interaction between the LR108 strain and the LP194 strain, and they can cooperate with each other to synergistically enhance the effects of regulating oral flora, inhibiting Porphyromonas gingivalis, reducing the release of inflammatory factors, and thus promoting oral health.

[0010] In the above-mentioned microbial preparations, the LR108 strain and the LP194 strain can exist in either a live bacterial state or an inactivated state. It is more preferred to use them in an inactivated state (postbiotics), because postbiotics are safer and more stable than live bacteria, giving them greater advantages in processing, transportation and storage. Compared with live probiotics, the longer shelf life ensures that postbiotic products can enter many areas with inconvenient transportation, making it easier to promote and expand their scope of use.

[0011] Preferably, the ratio of the bacterial count of the LR108 strain to the LP194 strain is 1:10-10:1, for example, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, etc. Other specific point values ​​within this numerical range can be selected, which will not be described here one by one.

[0012] Based on the potential interaction between the two strains in regulating oral flora, inhibiting Porphyromonas gingivalis, and reducing the release of inflammatory factors, the effect is better when the two meet the above-mentioned specific ratio relationship.

[0013] Preferably, the bacterial count of the strain in the microbial preparation is not less than 1×10 8 / g or 1×10 8 / mL, for example 1×10 8 pieces / g(pieces / mL), 1×10 9 pieces / g(pieces / mL), 1×10 10 pieces / g(pieces / mL), 5×10 10 pieces / g(pieces / mL), 1×10 11 pieces / g(pieces / mL), 3×10 11 pieces / g(pieces / mL), 5×10 11 pieces / g(pieces / mL), 1×10 12 pieces / g(pieces / mL), 1×10 13 Pieces / g (pieces / mL), etc. Other specific point values ​​within this numerical range can be selected and will not be described here one by one.

[0014] Preferably, the microbial preparation is in the form of a solution or a powder.

[0015] Preferably, the microbial preparation further contains any one of a functional aid, a protective agent, and a carrier, or a combination of at least two of them.

[0016] Preferably, the functional auxiliary agent includes any one of fructooligosaccharides, galacto-oligosaccharides, xylooligosaccharides, isomaltooligosaccharides, inulin, polydextrose, whey protein or lactoferrin, or a combination of at least two thereof.

[0017] Preferably, the protective agent comprises any one of skim milk, gelatin, gum arabic, dextran, polyvinyl pyrrolidone, sucrose, lactose, trehalose, sorbitol or xylitol, or a combination of at least two thereof.

[0018] Preferably, the carrier comprises any one of maltodextrin, starch, microcrystalline cellulose, calcium carbonate or calcium hydrogen phosphate, or a combination of at least two thereof.

[0019] In a second aspect, the present invention provides use of the microbial preparation for regulating oral flora according to the first aspect in the preparation of food or oral care products that promote oral health.

[0020] In a third aspect, the present invention provides use of the microbial preparation for regulating oral flora according to the first aspect in the preparation of a medicine for improving periodontitis.

[0021] Compared with the prior art, the present invention has the following beneficial effects:

[0022] The present invention develops a new probiotic intervention strategy for regulating oral flora, that is, Lactobacillus reuteri LR108 strain and Lactobacillus plantarum LP194 strain are compounded to form a new microbial preparation, which can regulate oral flora, has good copolymerization ability and inhibitory effect on Porphyromonas gingivalis growing in the oral cavity, reduces the colonization of Porphyromonas gingivalis in the oral cavity, reduces inflammatory factors, and thus promotes oral health. Among them, LR108 strain and LP194 strain have excellent self-aggregation and hydrophobicity, and have a positive effect on adhesion to the intestine. Moreover, when the amount of bacteria used is the same, the combination of the two strains significantly improves the above-mentioned effects compared with a single LR108 strain or a single LP194 strain. That is, there is a potential interaction between the LR108 strain and the LP194 strain, and they can cooperate with each other to synergistically enhance the effects of regulating oral flora, inhibiting Porphyromonas gingivalis, reducing the release of inflammatory factors, and thus promoting oral health.

[0023] The LR108 strain involved in the present invention is classified and named Limosilactobacillus reuteri, and the preservation unit is Guangdong Microbial Culture Collection Center. The preservation time is December 26, 2022, the preservation number is CDMCC No: 63095, and the address is: 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou.

[0024] The LP194 strain involved in the present invention is classified and named Lactobacillus plantarum, and the preservation unit is the General Microbiology Center of China Microorganism Culture Collection Administration. The preservation time is January 29, 2021, the preservation number is CGMCC 21766, and the address is: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing. DETAILED DESCRIPTION

[0025] In order to further explain the technical means and effects adopted by the present invention, the technical solution of the present invention is further described below in conjunction with the preferred embodiments of the present invention, but the present invention is not limited to the scope of the embodiments.

[0026] The LR108 strain involved in the following content is classified and named Lacticaseibacillus rhamnosus, the preservation date is December 26, 2022, and the preservation number is CDMCC No:63095.

[0027] The LP194 strain involved in the following content is classified and named Lactobacillus plantarum, the preservation date is January 29, 2021, and the preservation number is CGMCC 21766.

[0028] The culture medium formula involved in the following content is as follows:

[0029] MRS liquid culture medium: peptone 10 g, beef extract 10 g, glucose 20 g, lactose 10 g, yeast extract 5 g, diammonium hydrogen citrate 2 g, K2PO4·3H2O 2 g, MgSO4·7H2O 0.6 g, MnSO4 0.01 g, L-cysteine ​​1 g, water 1000 mL.

[0030] Preparation Example 1

[0031] This preparation example provides LR108 bacterial solution and LP194 bacterial solution, and the preparation method is as follows:

[0032] The seed liquid of LR108 strain and LP194 strain were inoculated into MRS culture medium at an inoculation amount of 3% of the total mass of the culture medium, and cultured at 37°C to obtain a bacterial suspension; high-temperature inactivation was performed at 120°C for 30 minutes, the inactivated bacterial suspension was transferred to a sterile centrifuge tube, the precipitate was collected by centrifugation, and it was resuspended with a sterile PBS buffer solution, and the centrifugation and resuspension were repeated twice to obtain an inactivated LR108 bacterial solution and a LP194 bacterial solution.

[0033] Example 1

[0034] Determination of self-agglutination properties:

[0035] Adjust the bacterial solution concentration to 1×10 8 / mL, stand at 25 ° C for 24 hours, measure the initial absorbance at 600nm (A0), take the bacterial suspension at 2, 4, 6, 12, and 24 hours to measure the absorbance at 600nm (absorbance at time t, At), measure three parallels at each time point, and calculate the self-agglutination rate of inactivated LR108 and inactivated LP194. The formula is: self-agglutination rate = (1-At / A0) × 100%. The results are shown in Table 1.

[0036] Table 1

[0037] Group 2h 4h 6h 12h 24h LR108 86.23％ 89.04％ 93.33％ 92.17％ 90.13％ LP194 85.36％ 88.60％ 93.24％ 92.30％ 90.09％

[0038] Example 2

[0039] Determination of hydrophobic properties:

[0040] Adjust the bacterial solution concentration to 1×10 8 / mL, let it stand at 25°C for 24h, measure the initial absorbance at 600nm (A0), then add an equal volume of xylene, shake and mix thoroughly, let it stand for 1h, measure the absorbance at 600nm of the water phase (A1), and calculate the hydrophobicity of inactivated LR108 and inactivated LP194, the formula is: hydrophobicity = (1-A1 / A0) × 100%. The results are shown in Table 2.

[0041] Table 2

[0042] Group Hydrophobicity LR108 88.59±3.67 LP194 87.46±4.13

[0043] Example 3

[0044] Determination of copolymerization properties:

[0045] The activated liquid of Porphyromonas gingivalis was inoculated into a 10 mL TSB medium + 5% defibrinated sheep blood test tube, and anaerobically cultured at 37° C. for 5 days to obtain a Porphyromonas gingivalis bacterial liquid.

[0046] Adjust the concentration of LR108 or LP194 bacterial solution to 1×10 8 / mL, and the concentration of Porphyromonas gingivalis was adjusted to 1×10 7 / mL, mix LR108 bacterial solution or LP194 bacterial solution with Porphyromonas gingivalis solution and place in a vortex mixer for 5 minutes to fully mix. Let stand at 37℃ for 24 hours, take the upper layer of the mixed bacterial solution at 0, 2, 4, 6, 12, and 24 hours to measure the absorbance at 600nm, and calculate the copolymerization rate according to the following formula:

[0047] Copolymerization rate (%) = [1-2At / (Ax+Ay)] × 100%

[0048] Where At represents the absorbance value of the upper layer of the mixed bacterial solution at each time point; Ax represents the absorbance value of the inactivated LR108 bacterial solution or LP194 bacterial solution at 0 h; Ay represents the absorbance value of the Porphyromonas gingivalis bacterial solution at 0 h.

[0049] The results are shown in Table 3.

[0050] Table 3

[0051] Group 2h 4h 6h 12h 24h LR108 73.84％ 75.83％ 77.57％ 78.91％ 79.84％ LP194 73.52％ 75.34％ 76.28％ 79.32％ 80.22％

[0052] From the data results in Tables 1 to 3, it can be seen that both the LR108 strain and the LP194 strain have excellent self-aggregation, hydrophobic and copolymerization properties.

[0053] Preparation Example 2

[0054] This preparation example provides LR108 bacterial powder and LP194 bacterial powder, and the preparation method is as follows:

[0055] The seed liquid of LR108 strain and LP194 strain were inoculated into MRS medium at an inoculation amount of 3% of the total mass of the medium, and the bacterial concentration was monitored to obtain fermentation liquid; the fermentation liquid was centrifuged at 5000rpm for 5 minutes at 4°C, and the lower layer of bacterial mud was taken; the bacterial mud was mixed with an aqueous solution containing 70% milk powder at a volume ratio of 1:1.5 to form an emulsion; the emulsion was sprayed into the fluidized bed of the granulation dryer as a slurry, and maltodextrin was directly added into the fluidized bed of the boiling granulation dryer, and the emulsion and maltodextrin formed round balls together, and the water was evaporated by hot air. The emulsion injection speed was controlled at 0.4L / min, the atomization pressure was 0.2MPa, the induced air frequency was 25Hz, the induced air temperature was 85°C, and the ratio of emulsion to malt paste was 2L:1kg to obtain inactivated LR108 bacterial powder and inactivated LP194 bacterial powder.

[0056] Example 4

[0057] Determination of antibacterial effect on Porphyromonas gingivalis:

[0058] The activated liquid of Porphyromonas gingivalis was inoculated into a 10 mL TSB medium + 5% defibrinated sheep blood test tube, and anaerobically cultured at 37° C. for 5 days to obtain a Porphyromonas gingivalis bacterial liquid.

[0059] The inactivated LR108 bacterial powder, inactivated LP194 bacterial powder, or a mixture of the two bacterial powders (the bacterial count ratio was 1:1) were diluted with physiological saline to obtain sample solutions of each group, with a concentration of 1×10 8 Pieces / mL.

[0060] Mark the position on the culture dish and take 150 μL of Porphyromonas gingivalis culture solution (1×10 7 / mL), pour 3mm blood agar plate medium, shake evenly, and after complete solidification, put Oxford cups at the marked position, add 150μL of each group of sample solutions to each Oxford cup, and set up a control group at the same time: replace the sample solution with sterile water. Put the plate in an incubator and culture it anaerobically at 37℃ for 6 days, and observe the size of the inhibition zone on each plate. The results are shown in Table 4.

[0061] Table 4

[0062] Group Diameter of inhibition zone (mm) LR108 25 LP194 24 LR108+LP194 27

[0063] From the data results in Table 4, it can be seen that the microbial preparation involved in the present invention has an excellent effect of inhibiting Porphyromonas gingivalis, and the LR108 strain and the LP194 strain have a synergistic effect in inhibiting Porphyromonas gingivalis.

[0064] Example 5

[0065] Determination of the inhibitory effect on Porphyromonas gingivalis biofilm:

[0066] The activated liquid of Porphyromonas gingivalis was inoculated into a 10 mL TSB medium + 5% defibrinated sheep blood test tube and cultured anaerobically at 37°C for 5 days to obtain the Porphyromonas gingivalis liquid. The concentration was adjusted to 1×10 8 The inactivated LR108 bacterial powder, the inactivated LP194 bacterial powder, or the mixture of the two bacterial powders (the bacterial count ratio was 1:1) were diluted with physiological saline to obtain sample solutions of each group, with a concentration of 1×10 8 The Porphyromonas gingivalis bacterial solution was mixed with an equal volume of each sample solution as the experimental group; the Porphyromonas gingivalis bacterial solution was mixed with an equal volume of PBS solution as the control group.

[0067] 200 μL of each mixed solution was added to a 96-well plate, and the plate was incubated anaerobically at 37°C for 24 hours. The culture medium of each well was carefully sucked off to remove free bacteria. Each well was washed 3 times with 200 μL of PBS buffer, and then 100 μL of 1% crystal violet solution was added to each well after standing and drying at room temperature. The plate was stained for 15 minutes at room temperature to color the attached bacteria. After the staining solution was removed, the plate was washed 4 times with PBS buffer. After drying, 100 μL of 95% ethanol was added to each well to dissolve the stained biofilm. The plate was decolorized by shaking horizontally at a low speed at 25°C for 20 minutes. After decolorization, the absorbance value was read at OD550nm using an enzyme marker, which was the obtained value. The results are shown in Table 5.

[0068] Table 5

[0069] Group OD550nm PBS 0.271±0.024 LR108 0.065±0.005 LP194 0.063±0.007 LR108+LP194 0.052±0.005

[0070] It can be seen from the data results in Table 5 that the microbial preparation involved in the present invention has an excellent effect of inhibiting the biofilm of Porphyromonas gingivalis, and the LR108 strain and the LP194 strain have a synergistic effect in the above-mentioned efficacy.

[0071] Example 6

[0072] Evaluation of the effect of alleviating periodontitis in rats:

[0073] (1) Experimental animals: 5-week-old SPF male Wistar rats were free of specific pathogens. The rats were housed in an SPF experimental animal room at 25°C with 12 hours of light per day, and were allowed to acclimate for 7 days with ventilation maintained.

[0074] (2) Animal grouping: After one week of adaptive feeding, 64 rats were randomly divided into 8 groups (8 rats in each group):

[0075] (2.1) Control group: fed with normal feed and free access to water;

[0076] (2.2) Model group: 200 μL of Porphyromonas gingivalis suspension was used every day (10 9 CFU / mL) were wiped, and feeding and drinking were prohibited within 1 hour after wiping to ensure that the rats were colonized in the oral cavity. The modeling lasted for 1 week;

[0077] (2.3) rat group treated with inactivated LR108 powder and inactivated LP194 powder (LR108+LP194 group 1, the bacterial count ratio of the two bacteria was 1:1);

[0078] (2.4) rat group treated with inactivated LR108 powder and inactivated LP194 powder (LR108+LP194 group 2, the bacterial count ratio of the two bacteria was 10:1);

[0079] (2.5) rat group treated with inactivated LR108 powder and inactivated LP194 powder (LR108+LP194 group 3, the bacterial count ratio of the two bacteria was 1:10);

[0080] (2.6) rat group treated with inactivated LR108 powder (LR108 group);

[0081] (2.7) rat group treated with inactivated LP194 bacterial powder (LP194 group);

[0082] (2.8) A rat group treated with a combination of inactivated commercially available Lactobacillus reuteri ATCC23272 powder and inactivated commercially available Lactobacillus plantarum ATCC8014 powder (ATCC23272+ATCC8014 group, the bacterial count ratio of the two bacteria was 1:1).

[0083] Each probiotic intervention group used 200 μL of Porphyromonas gingivalis suspension (10 9 CFU / mL) for 1 week; then 200 μL of probiotic suspension (10 9 CFU / mL) swab for 3 weeks, and during the experimental period, the rats were fed with cariogenic Keyes 2000 diet and drinking water supplemented with 10% sucrose.

[0084] (3) Index detection:

[0085] (3.1) Changes of Porphyromonas gingivalis in rat oral cavity:

[0086] The rats were sampled at the 3rd, 4th and 5th weeks of the experiment. The samples were diluted and applied to TSA plates supplemented with 12 μg / mL ampicillin and 5% defibrinated sheep blood for viable bacterial counts, and the colonization of Porphyromonas gingivalis in the rats' mouths was counted (1 g CFU / mL). The results are shown in Table 6.

[0087] Table 6

[0088] Group Porphyromonas gingivalis count (lg CFU / mL) Control group ND Model Group 5.85±0.12 LR108 Group 3.44±0.15 LP194 Group 3.76±0.29 LR108+LP194 Group 1 2.96±0.24 LR108+LP194 Group 2 2.83±0.36 LR108+LP194 Group 3 2.90±0.73 ATCC23272+ATCC8014 group 3.98±0.47

[0089] It can be seen from the data results in Table 6 that after intervention with the microbial preparation involved in the present invention, the number of Porphyromonas gingivalis colonization in the rat oral cavity was significantly reduced, indicating that the microbial preparation can effectively improve the oral environment and be used to prevent or treat periodontitis, and the LR108 strain and the LP194 strain have a synergistic effect in the above-mentioned effects.

[0090] (3.2) Inflammatory factors in rat periodontal tissues:

[0091] After the experiment, the periodontal tissues of the rats in each group were cut, PBS buffer was added, homogenized by homogenizer, and the supernatant was collected by centrifugation. The levels of inflammatory factors IL-8 and IL-10 in the periodontal tissues of the rats were detected by enzyme-linked immunosorbent assay according to the kit operation. The results are shown in Table 7.

[0092] Table 7

[0093]

[0094]

[0095] It can be seen from the data results in Table 7 that after intervention with the microbial preparation involved in the present invention, the level of pro-inflammatory factor IL-8 in rat periodontal tissue was significantly reduced, and the level of anti-inflammatory factors was significantly increased, indicating that the microbial preparation can significantly improve periodontal tissue inflammation, and the LR108 strain and the LP194 strain have a synergistic effect in the above-mentioned effects.

[0096] The applicant declares that the present invention illustrates the technical solution of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

[0097] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.

[0098] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.

Claims

1. A microbial preparation for regulating oral flora, characterized in that: The strains in the microbial preparation for regulating oral flora are composed of Lactobacillus reuteriLR108 strain with a preservation number of GDMCC No: 63095 and Lactobacillus plantarum LP194 strain with a preservation number of CGMCC 21766.

2. The microbial preparation for regulating oral flora according to claim 1, characterized in that: The ratio of the bacterial count of the LR108 strain to that of the LP194 strain is 1:10-10:

1.

3. The microbial preparation for regulating oral flora according to claim 1, characterized in that: The bacterial count of the strain in the microbial preparation is not less than 1×10 8 / g or 1×10 8 Pieces / mL.

4. The microbial preparation for regulating oral flora according to claim 1, characterized in that: The dosage form of the microbial preparation includes solution or powder.

5. The microbial preparation for regulating oral flora according to claim 1, characterized in that: The microbial preparation also contains any one of a functional aid, a protective agent, and a carrier, or a combination of at least two of them.

6. The microbial preparation for regulating oral flora according to claim 5, characterized in that: The functional auxiliary agent includes any one of fructooligosaccharide, galacto-oligosaccharide, xylooligosaccharide, isomaltooligosaccharide, inulin, polydextrose, whey protein or lactoferrin, or a combination of at least two of them.

7. The microbial preparation for regulating oral flora according to claim 5, characterized in that: The protective agent includes any one of skim milk, gelatin, gum arabic, dextran, polyvinyl pyrrolidone, sucrose, lactose, trehalose, sorbitol or xylitol, or a combination of at least two thereof.

8. The microbial preparation for regulating oral flora according to claim 5, characterized in that: The carrier includes any one of maltodextrin, starch, microcrystalline cellulose, calcium carbonate or calcium hydrogen phosphate, or a combination of at least two thereof.

9. Use of the microbial preparation for regulating oral flora according to any one of claims 1 to 8 in the preparation of food or oral care products that promote oral health.

10. Use of the microbial preparation for regulating oral flora according to any one of claims 1 to 8 in the preparation of a medicine for improving periodontitis.

Images